• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于前列腺特异性膜抗原的低分子量荧光成像剂的合成与生物评价。

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

机构信息

Russell H. Morgan Department of Radiology, Brain Science Institute, Johns Hopkins Medical School, Baltimore, MD 21231, USA.

出版信息

Bioconjug Chem. 2012 Dec 19;23(12):2377-85. doi: 10.1021/bc3003919. Epub 2012 Dec 4.

DOI:10.1021/bc3003919
PMID:23157641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4131203/
Abstract

Targeted near-infrared (NIR) optical imaging can be used in vivo to detect specific tissues, including malignant cells. A series of NIR fluorescent ligands targeting the prostate-specific membrane antigen (PSMA) was synthesized and each compound was tested for its ability to image PSMA+ tissues in experimental models of prostate cancer. The agents were prepared by conjugating commercially available active esters of NIR dyes, including IRDye800CW, IRDye800RS, Cy5.5, Cy7, or a derivative of indocyanine green (ICG) to the terminal amine group of (S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid 1, (14S,18S)-1-amino-8,16-dioxo-3,6-dioxa-9,15,17-triazaicosane-14,18,20-tricarboxylic acid 2 and (3S,7S)-26-amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid 3. The K(i) values for the dye-inhibitor conjugates ranged from 1 to 700 pM. All compounds proved capable of imaging PSMA+ tumors selectively to varying degrees depending on the choice of fluorophore and linker. The highest tumor uptake was observed with IRDye800CW employing a poly(ethylene glycol) or lysine-suberate linker, as in 800CW-2 and 800CW-3, while the highest tumor to nontarget tissue ratios were obtained for Cy7 with these same linkers, as in Cy7-2 and Cy7-3. Compounds 2 and 3 provide useful scaffolds for targeting of PSMA+ tissues in vivo and should be useful for preparing NIR dye conjugates designed specifically for clinical intraoperative optical imaging devices.

摘要

靶向近红外(NIR)光学成像是一种可以在体内用于检测特定组织的方法,包括恶性细胞。我们合成了一系列靶向前列腺特异性膜抗原(PSMA)的 NIR 荧光配体,并且每种化合物都经过了测试,以评估其在前列腺癌实验模型中成像 PSMA+组织的能力。这些试剂是通过将市售的 NIR 染料的活性酯,包括 IRDye800CW、IRDye800RS、Cy5.5、Cy7 或吲哚菁绿(ICG)的衍生物,连接到(S)-2-(3-((S)-5-氨基-1-羧基戊基)脲基)戊二酸 1、(14S,18S)-1-氨基-8、16-二氧代-3、6-二氧杂-9、15、17-三氮杂icosane-14、18、20-三羧酸 2 和(3S,7S)-26-氨基-5、13、20-三氧代-4、6、12、21-四氮杂二十六烷-1、3、7、22-四羧酸 3 的末端氨基上而制备的。染料抑制剂缀合物的 K(i) 值范围为 1 至 700 pM。所有化合物都能够根据荧光团和连接子的选择,在不同程度上选择性地对 PSMA+肿瘤进行成像。观察到具有最高肿瘤摄取的是使用聚(乙二醇)或赖氨酸琥珀酸盐连接子的 IRDye800CW,如 800CW-2 和 800CW-3,而对于具有相同连接子的 Cy7 则获得了最高的肿瘤与非靶组织比值,如 Cy7-2 和 Cy7-3。化合物 2 和 3 为体内靶向 PSMA+组织提供了有用的支架,并且应该有助于制备专门为临床术中光学成像设备设计的 NIR 染料缀合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/e5ce119a79ab/nihms610645f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/68ef88b949b6/nihms610645f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/2c6e30f53056/nihms610645f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/e0681c6a5fde/nihms610645f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/c52e2be8f4b5/nihms610645f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/ac1d223842fe/nihms610645f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/e5ce119a79ab/nihms610645f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/68ef88b949b6/nihms610645f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/2c6e30f53056/nihms610645f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/e0681c6a5fde/nihms610645f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/c52e2be8f4b5/nihms610645f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/ac1d223842fe/nihms610645f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2143/4131203/e5ce119a79ab/nihms610645f6.jpg

相似文献

1
Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.用于前列腺特异性膜抗原的低分子量荧光成像剂的合成与生物评价。
Bioconjug Chem. 2012 Dec 19;23(12):2377-85. doi: 10.1021/bc3003919. Epub 2012 Dec 4.
2
Cy7-(3,7)-26-Amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acidCy7-(3,7)-26-氨基-5,13,20-三氧代-4,6,12,21-四氮杂二十六烷-1,3,7,22-四羧酸
3
A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents.一系列 PSMA 靶向近红外荧光成像剂。
Biomolecules. 2022 Mar 5;12(3):405. doi: 10.3390/biom12030405.
4
In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.用于成像前列腺特异性膜抗原表达组织的近红外和IRDye800CW标记的聚乳酸-聚乙二醇纳米颗粒
Biomacromolecules. 2017 Jan 9;18(1):201-209. doi: 10.1021/acs.biomac.6b01485. Epub 2016 Dec 21.
5
A low molecular weight PSMA-based fluorescent imaging agent for cancer.一种用于癌症的基于低分子量前列腺特异性膜抗原的荧光成像剂。
Biochem Biophys Res Commun. 2009 Dec 18;390(3):624-9. doi: 10.1016/j.bbrc.2009.10.017. Epub 2009 Oct 8.
6
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.新型谷氨酸-尿素-赖氨酸类似物作为前列腺癌分子成像药物靶向前列腺特异性膜抗原的临床前评估。
Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.
7
PSMA-targeted NIR probes for image-guided detection of prostate cancer.PSMA 靶向近红外探针用于前列腺癌的影像引导检测。
Colloids Surf B Biointerfaces. 2022 Oct;218:112734. doi: 10.1016/j.colsurfb.2022.112734. Epub 2022 Jul 28.
8
Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.设计并合成一种新型的 BODIPY 标记的 PSMA 抑制剂。
Bioorg Med Chem Lett. 2020 Feb 1;30(3):126894. doi: 10.1016/j.bmcl.2019.126894. Epub 2019 Dec 18.
9
Development of targeted near-infrared imaging agents for prostate cancer.用于前列腺癌的靶向近红外成像剂的研发
Mol Cancer Ther. 2014 Nov;13(11):2595-606. doi: 10.1158/1535-7163.MCT-14-0422. Epub 2014 Sep 19.
10
Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.作为前列腺特异性膜抗原的光学成像探针,带有不同近红外荧光团的琥珀酰亚胺基-Cys-C(O)-Glu 衍生物的结构-活性关系。
Bioorg Med Chem. 2018 May 15;26(9):2291-2301. doi: 10.1016/j.bmc.2018.03.015. Epub 2018 Mar 10.

引用本文的文献

1
Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer.靶向前列腺特异性膜抗原的前药用于治疗前列腺癌
J Med Chem. 2025 Jun 26;68(12):12296-12330. doi: 10.1021/acs.jmedchem.4c02626. Epub 2025 Jun 12.
2
Recent Advances in Therapeutic Peptides: Innovations and Applications in Treating Infections and Diseases.治疗性肽的最新进展:在治疗感染和疾病中的创新与应用
ACS Omega. 2025 Apr 23;10(17):17087-17107. doi: 10.1021/acsomega.5c02077. eCollection 2025 May 6.
3
A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer.

本文引用的文献

1
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.18F-DCFBC(一种低分子量前列腺特异性膜抗原抑制剂)在转移性前列腺癌患者中的生物分布、肿瘤检测和辐射剂量学。
J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661.
2
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.[68Ga]镓标记的前列腺特异性膜抗原(PSMA)配体作为诊断前列腺癌的优质正电子发射断层显像(PET)示踪剂:与18F-FECH的比较
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6. doi: 10.1007/s00259-012-2069-0. Epub 2012 Feb 4.
3
联合化疗和光动力疗法根除前列腺癌的协同策略。
Int J Mol Sci. 2024 Jun 28;25(13):7086. doi: 10.3390/ijms25137086.
4
Peptide Assemblies for Cancer Therapy.肽组装用于癌症治疗。
ChemMedChem. 2023 Sep 1;18(17):e202300258. doi: 10.1002/cmdc.202300258. Epub 2023 Jul 20.
5
Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging.表达胃泌素释放肽受体的实体瘤的术前和术中可视化:用于核成像和荧光成像的新型双模态探针的临床前分析
Cancers (Basel). 2023 Apr 5;15(7):2161. doi: 10.3390/cancers15072161.
6
The application of indocyanine green in guiding prostate cancer treatment.吲哚菁绿在指导前列腺癌治疗中的应用。
Asian J Urol. 2023 Jan;10(1):1-8. doi: 10.1016/j.ajur.2021.07.004. Epub 2022 Apr 22.
7
Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate.小分子前列腺特异性膜抗原靶向阿比特龙缀合物的合成及临床前评价。
Molecules. 2022 Dec 12;27(24):8795. doi: 10.3390/molecules27248795.
8
Affinity probes based on small-molecule inhibitors for tumor imaging.基于小分子抑制剂的亲和探针用于肿瘤成像。
Front Oncol. 2022 Oct 27;12:1028493. doi: 10.3389/fonc.2022.1028493. eCollection 2022.
9
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.前列腺癌的光动力疗法:最新进展、挑战与机遇
Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022.
10
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells and .靶向c-Met的嵌合抗原受体T细胞抑制肝癌细胞 以及 。 (原文句末不完整,翻译可能存在一定局限性)
J Biomed Res. 2021 Dec 16;36(1):10-21. doi: 10.7555/JBR.35.20200207.
GCPII imaging and cancer.
GCPII 成像与癌症。
Curr Med Chem. 2012;19(9):1346-59. doi: 10.2174/092986712799462612.
4
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
5
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.使用前列腺特异性膜抗原双模态抑制剂对前列腺癌实验模型进行序贯单光子发射计算机断层扫描和光学成像
Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70. doi: 10.1002/anie.201102872. Epub 2011 Aug 22.
6
Optical imaging in cancer research: basic principles, tumor detection, and therapeutic monitoring.光学成象在癌症研究中的应用:基本原理、肿瘤检测和治疗监测。
Med Princ Pract. 2011;20(5):397-415. doi: 10.1159/000327655. Epub 2011 Jul 11.
7
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.利用淬灭的人源化 J591 抗体-吲哚菁绿(ICG)缀合物,对前列腺特异性膜抗原(PSMA)阳性肿瘤进行靶向、可激活、体内荧光成像。
Bioconjug Chem. 2011 Aug 17;22(8):1700-5. doi: 10.1021/bc2002715. Epub 2011 Jul 27.
8
Radical prostatectomy versus watchful waiting in early prostate cancer.根治性前列腺切除术与早期前列腺癌的观察等待。
N Engl J Med. 2011 May 5;364(18):1708-17. doi: 10.1056/NEJMoa1011967.
9
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery.吲哚菁绿作为一种近红外荧光对比剂在影像引导肿瘤外科手术中的临床应用。
J Surg Oncol. 2011 Sep 1;104(3):323-32. doi: 10.1002/jso.21943. Epub 2011 Apr 14.
10
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.一种用于前列腺癌的靶向低分子量近红外荧光探针。
Bioorg Med Chem Lett. 2010 Dec 1;20(23):7124-6. doi: 10.1016/j.bmcl.2010.09.057. Epub 2010 Sep 17.